AOD-9604 Australia

AOD-9604 Australia. AOD-9604 is the fat metabolism fragment. The research reports faster breakdown of stored fat, fewer new fat cells forming, and lower body weight in obese animal models. What it also reports is just as much the point: IGF-1, blood sugar and insulin sensitivity all stay unchanged. A separate, later strand studies it in cartilage and osteoarthritis.

How it does it. Growth hormone is a large molecule doing several unrelated jobs, and the part at its tail end is the part tied to how the body handles fat. AOD-9604 is that fragment, residues 177 to 191 plus one extra amino acid, made as a standalone molecule. Separating it is the whole point, because it isolates the fat metabolism signal from the growth and blood sugar effects of the intact hormone. The pathway it is studied against is the β3-adrenergic receptor, which sits on fat cells.

The vial. Independently HPLC-tested above 99% purity by Janoshik, with the certificate of analysis published on this page and in the lab-reports library. That is the measured number, not a marketing figure, and it carries a verifiable Janoshik key. Supplied in a 5 mg freeze-dried vial, dispatched from Australia, AUD pricing. Supplied strictly for in-vitro and laboratory research use only. Not for human or animal consumption, not a therapeutic good, not TGA-approved.

AOD-9604 (CAS 221231-10-3; molecular formula C78H123N23O23S2, average molecular weight ≈ 1815 g/mol) is a 16-residue synthetic peptide — the sequence Tyr-hGH(177-191). It corresponds to the C-terminal lipolytic fragment of the human growth-hormone molecule, with an added N-terminal tyrosine; an intramolecular disulfide bridge between its two cysteine residues forms a small loop that mirrors the native hGH C-terminal loop. It is a distinct research entity from the intact 191-residue hormone.

In receptor and pathway research, AOD-9604 is studied as a probe of the growth-hormone lipolytic pathway that is structurally separable from the somatogenic, IGF-1-mediated actions of the intact hormone. The original metabolic characterisation of the synthetic fragment was reported by Ng and colleagues (Hormone Research, 2000), and Heffernan and colleagues (Endocrinology, 2001) used β3-adrenergic-receptor knock-out models to probe the pathway implicated in the fragment’s lipid-metabolic signalling — the reason the β3-adrenergic receptor is referenced across AOD-9604 research literature.

Because the peptide is a defined synthetic fragment, it is also studied as an analytical reference: Cox and colleagues (Drug Testing and Analysis, 2015) characterised its detection and in-vitro metabolic breakdown products. Together these give AOD-9604 a well-described identity in lipid-metabolism and growth-hormone-fragment research contexts.

The lipolytic activity of growth hormone was localised to its C-terminal region before AOD-9604 was designed; the peptide represents that domain as a discrete, disulfide-stabilised sequence, which is why it is used to study the lipid-metabolic signal in isolation from the hormone’s receptor-mediated growth axis. As a short, defined synthetic sequence it reconstitutes and stores predictably, making it a convenient reference compound for adipocyte and lipid-metabolism assays rather than a probe of the intact 191-residue hormone.

The information provided here is a research-reference summary only. Elite AU Peptides makes no medical, therapeutic, fat-loss, weight-loss, body-composition, or human-use claim about this product. AOD-9604 is not TGA-approved, is not a therapeutic good, and is supplied strictly for in-vitro and laboratory research use only. Researchers should consult the primary peer-reviewed literature for pathway data and protocol-specific reference values.

Reconstitute the lyophilised AOD-9604 vial with bacteriostatic water for laboratory handling. Add the diluent slowly down the vial wall and swirl gently rather than shaking. The required volume depends on your research protocol and target working concentration — a 5 mg vial reconstituted in 2 mL of bacteriostatic water yields a 2.5 mg/mL working stock.

Store the lyophilised powder at −20°C, desiccated and protected from light; once reconstituted, store refrigerated at 2–8°C and use within the documented research window, or aliquot and freeze to avoid repeated freeze-thaw cycles. Tamper-evident packaging; the batch label is the canonical reference for the certificate of analysis published in the lab-reports library.

Shop bacteriostatic water · Reconstitution calculator

Australia only. Free shipping over $100. Orders placed before 12pm AEST are dispatched the same business day from Australia.

30-day returns on unused product in original packaging, with prior approval.